<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148053</url>
  </required_header>
  <id_info>
    <org_study_id>CTB18001</org_study_id>
    <nct_id>NCT04148053</nct_id>
  </id_info>
  <brief_title>Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis</brief_title>
  <official_title>Evaluation of TB-antigen Responsive T Cell Markers in Diagnosis of Tuberculosis and Extrapulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis of active and latent pulmonary tuberculosis, as well as extrapulmonary
      tuberculosis, is still a major challenge of TB control in China. This observational study
      aims to evaluate TB-antigen responsive T cell markers in the diagnosis of tuberculosis and
      extrapulmonary tuberculosis and try to find new prompt and cost-effective laboratory tests
      for active TB screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The enrolled patients will be grouped into active or latent tuberculosis according to the
      bacteriological evidence of TB. The TB-antigen responsive T cell markers will be examined.
      The performance of each T cell marker for the diagnosis of active TB will be systematically
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive rate and negative rate</measure>
    <time_frame>2-3 month after sampling</time_frame>
    <description>Evaluation of the positive rate and negative rate for each T cell marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Receiver operating characteristic curve</measure>
    <time_frame>2-3 month after sampling</time_frame>
    <description>The AUC of each T cell marker will be analyzed and compared</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>Active TB</arm_group_label>
    <description>Subjects met the following:
Either Pulmonary or Extra-pulmonary tuberculosis patients
TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latent TB</arm_group_label>
    <description>Subjects met the following:
TB Contact in history.
Chest X-ray suggestive of non-TB.
without any symptoms suggestive of TB.
TST and/or IGRA positive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TB-antigen responsive T cell markers</intervention_name>
    <description>A blood test including a series of T cell markers which are responsive to TB antigens</description>
    <arm_group_label>Active TB</arm_group_label>
    <arm_group_label>Latent TB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients suspicious of TB infection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patients suspicious of TB infection

          -  TB culture and Xpert test required

          -  Chest X-ray required

        Exclusion Criteria:

          -  anti-TB therapy before the sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BO SU, Dr</last_name>
    <phone>86-021-65115006</phone>
    <phone_ext>3039</phone_ext>
    <email>su_bo_s@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BO SU, Dr.</last_name>
      <phone>86-021-65115006</phone>
      <phone_ext>3039</phone_ext>
      <email>su_bo_s@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Bo SU, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WEI SHA, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Fan, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaojun Yang, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Na Wang, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji University</investigator_affiliation>
    <investigator_full_name>Caicun Zhou</investigator_full_name>
    <investigator_title>Director, Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The sharing of individual participant data will be decided by the sponsor after the accomplishment of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

